<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Curr Emerg Hosp Med Rep</span><span class="iso-abbrev" title="iso-abbrev">Curr Emerg Hosp Med Rep</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Current Emergency and Hospital Medicine Reports</span></div><span class="issn-epub" tagx="issn" title="issn-epub">2167-4884</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Springer US</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">New York</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7296288">7296288</a></span><span class="publisher-id" title="publisher-id">218</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1007/s40138-020-00218-1">10.1007/s40138-020-00218-1</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Infectious Disease (J Glauser, Section Editor)</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">http://orcid.org/0000-0002-5860-5606</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Garber</span><span class="given-names" tagx="given-names" title="given-names">Boris</span></span><span class="address" title="address"><span class="email" tagx="email" title="email">bgarber@metrohealth.org</span></span><a href="#Aff1" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Glauser</span><span class="given-names" tagx="given-names" title="given-names">Jonathan</span></span><a href="#Aff1" /></span><span class="citation_author_institution" id="Aff1">[], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">grid.67105.35</span><span class="institution-id" title="institution-id">0000 0001 2164 3847</span><span class="institution" title="institution">MetroHealth Medical Center, </span><span class="institution" title="institution">Case Western Reserve School of Medicine, </span></div></span></div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-6-6</span></span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">6</span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="purposeofreview" title="sec"> <div class="title" tagx="title" title="title">
Purpose of Review</div> <p id="Par1">We discuss and review new antimicrobials for treatment of bacterial, viral, fungal, and parasitic infections with indications, contraindications, and side effects for each. We will also review new information and indications on older agents that are relevant to clinical practice. Many of them may be unfamiliar to Emergency Physicians given their newness and at times hospital restrictions on their use. We also review some new promising agents that are not yet in the clinical pipeline.</p> </div> <div class="recentfindings" title="sec"> <div class="title" tagx="title" title="title">
Recent Findings</div> <p id="Par2">As new antibiotics become available for clinicians to use, new information becomes available with respect to the drugsâ€™ indications, efficacy, pathogen resistance, drug-drug interactions, and side effects.</p> </div> <div class="summary" title="sec"> <div class="title" tagx="title" title="title">
Summary</div> <p id="Par3">This article provides Emergency Department clinicians with a useful summary with new information on antibiotic use and recent research into agents which may become available.</p> </div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Antibiotic</div> <div class="kwd" title="kwd">
Resistance</div> <div class="kwd" title="kwd">
Emergency</div> <div class="kwd" title="kwd">
Development</div> </div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"> <div class="title" tagx="title" title="title">
Introduction</div> <p id="Par4">Antibiotics play a critical role in pharmacological management of Emergency Department patients presenting with apparent infectious disease [<a href="#CR1">1</a>]. Antibiotic resistance development is a constant threat whether bacterial, viral, or fungal infections are concerned [<a href="#CR2">2</a>â€¢, <a href="#CR3">3</a>â€¢â€¢, <a href="#CR4">4</a>]. As the new agents emerge and become available for clinical use, some antimicrobials lose effectiveness in some areas, while others become repurposed for a new indication. As multidrug resistant organisms increase in prevalence so is the need for antimicrobial polypharmacy early on in the management of the critically ill infected patients as well as prolonged courses of antibiotics, increasingly done on an outpatient basis [<a href="#CR2">2</a>â€¢, <a href="#CR5">5</a>]. Whether the Emergency Physician initiates treatment with an antimicrobial or is faced with a patient already taking one, a good understanding of shifting indications and contraindications for their use as well as drug-drug interactions and side effects continues to be important. Thus, staying abreast of new developments in infectious disease pharmaceutical armamentarium is a must for Emergency Medicine providers.</p> </div> <div class="antibioticresistance" title="sec"> <div class="title" tagx="title" title="title">
Antibiotic Resistance</div> <p id="Par5">Antibiotic-resistant bacteria continue to spread worldwide and are a persistent and severe health threat [<a href="#CR2">2</a>â€¢] with morbidity and mortality increasing annually [<a href="#CR6">6</a>]. There are multiple implications to physicians caring for patients with presentations concerning for infectious etiology, including the frequent need for early administration of multiple broad-spectrum antibiotics [<a href="#CR7">7</a>]. Emergency Departments (EDs) are a common entry point for care for patients with a range of infectious diseases [<a href="#CR3">3</a>â€¢â€¢], and ED physicians are on the front line for early and sometimes the only antibacterial therapy choice for these patients. Patients affected by extended spectrum Î²-lactamaseâ€"producing and colistin-resistant <i>Pseudomonas aeruginosa</i>, carbapenem-resistant Enterobacteriaceae, methicillin-resistant <i>Staphylococcus aureus</i>, and drug-resistant <i>Neisseria gonorrhoeae</i> are encountered routinely in US Emergency Departments [<a href="#CR3">3</a>â€¢â€¢]. Multidrug-resistant bacteria are affecting all populations and have been implicated even in neonatal sepsis requiring broader coverage in that patient group [<a href="#CR8">8</a>, <a href="#CR9">9</a>]. It is important for ED providers to stay abreast of new therapies and concepts for these common and serious infections [<a href="#CR3">3</a>â€¢â€¢].</p> <p id="Par6">Antibiotic resistance development is not limited to bacteria; it involves all human pathogens. Pathogenic viruses have been known to become resistant to antivirals, with influenza A and B now commonly resistant to adamantane compounds and occasionally resistant to newer neuraminidase inhibitors [<a href="#CR4">4</a>, <a href="#CR10">10</a>]. Several antiviral compounds are being currently studied, including favipiravir and fludase with potential broad activity against many pathogenic RNA viruses such as Ebola, West Nile, rabies, and Zika in addition to influenza viruses [<a href="#CR10">10</a>]. Another drug in clinical trials for influenza treatment is the neuraminidase inhibitor laninamivir which would be available as a nasal inhalation if approved [<a href="#CR11">11</a>]. Nitazoxanide, an antiparasitic agent, used to treat cryptosporidium infection in AIDS patients is currently in trials for influenza treatment due to its apparent antiviral activity [<a href="#CR11">11</a>]. Development of a more effective flu vaccine would do much to control influenza epidemics [<a href="#CR4">4</a>]. As far as other viral diseases are concerned, Presatovir (GS-5806) is in trials for Respiratory Syncytial Virus infection [<a href="#CR11">11</a>] and sofosbuvir, a drug previously approved for hepatitis C treatment, is in trials for treatment of Zika virus infection [<a href="#CR12">12</a>]. While several new compounds are being studied, nothing new has become available for herpes virus illnesses since our last update[<a href="#CR13">13</a>].</p> <p id="Par7">Recently, several fungal disease outbreaks have been noted worldwide, ranging from keratitis in contact lens wearers to health careâ€"associated fungal infections with high mortality [<a href="#CR14">14</a>]. Even as both invasive fungal infections and fungal resistance to currently limited antifungal drugs are becoming more common, and there are several molecules being studied for a number of fungal diseases [<a href="#CR15">15</a>], there have not been any new antifungals approved for use in the USA since our last review in 2017. Some strains of <i>Candida glabrata</i> and <i>auris</i> implicated in disseminated disease are now multidrug resistant [<a href="#CR16">16</a>].</p> <p id="Par8">The risk factors for infection with antibiotic-resistant bacteria include prior history of such an infection, chronic vascular access or chronic wound, and immunocompromised status stemming from chronic severe illness, malignancy, or primary immunologic defects [<a href="#CR3">3</a>â€¢â€¢]. The need to use broad-spectrum antibiotics liberally and early unfortunately contributes to constantly emerging and evolving patterns of pathogen resistance [<a href="#CR9">9</a>, <a href="#CR17">17</a>]. Meanwhile, it has become a routine to use antibiotics liberally in situations where previously they were used infrequently, such as in patients with simple skin abscesses [<a href="#CR18">18</a>].</p> <p id="Par9">Several pathogens were recently identified by the World Health Organization (WHO) as a critical priority, based on mortality, health care burden, and prevalence of resistance [<a href="#CR1">1</a>, <a href="#CR7">7</a>] (Table <a href="#Tab1">1</a>). The only two new antibacterial classes to be approved in the past 20Â yearsâ€"lipopeptides and oxazolidinonesâ€"are active against gram-positive pathogens [<a href="#CR1">1</a>]. Quinolones, which first appeared in 1960, was the last novel class of antibiotics discovered to be active against gram-negative bacteria [<a href="#CR1">1</a>]. Unfortunately many large pharmaceutical companies have limited investment into research in the past decade to discover new antibiotics in part due to negative financial incentives [<a href="#CR19">19</a>]. By definition, antimicrobials are meant in general to cure disease rather than to be taken forever as, for example, medications to treat diabetes or hypertension. Furthermore, antimicrobial husbandry includes attempts to limit pathogen resistance by limiting the time course of treatment. Additionally, the FDA requires that new agents for use in simple infections show superiority, which would require a very large number of subjects enrolled in a study, since most of these infections resolve spontaneously [<a href="#CR19">19</a>]. <div class="table-wrap_UNKNOWN" id="Tab1"><span class="label" tagx="label" title="label">Table 1</span> </div></p><p>Critical priority bacteria according to WHO [<a href="#CR1">1</a>, <a href="#CR2">2</a>â€¢]</p>  <table frame="hsides" rules="groups"> <tbody> <tr> <td colspan="2">Multidrug-resistant tuberculosis, Carbapenem-resistant <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i>, carbapenem and third-generation cephalosporin-resistant Enterobacteriaceae, vancomycin-resistant <i>Enterococcus faecium</i>, methicillin-resistant <i>Staphylococcus aureus</i>, clarithromycin-resistant <i>Helicobacter pylori</i>, fluoroquinolone-resistant Campylobacter spp., <i>Neisseria gonorrhoeae</i>, and <i>Salmonella typhi</i></td> </tr> </tbody> </table>  <p /> <p id="Par10">Infections caused by resistant bacteria cause up to two-fold increase in adverse outcomes, even when the pathogen remains susceptible to the antibiotic but a higher minimal inhibitory concentration (MIC) is present [<a href="#CR20">20</a>â€¢], especially if septic shock develops [<a href="#CR21">21</a>]. This contributes to the need to use antibiotics in higher doses and for longer courses. There is evidence that even Î²-lactams in high concentrations can produce a range of organ toxicity especially in the critically ill, including neurologic, hepatic, renal, and hematological side effects whose frequency may be currently underestimated [<a href="#CR22">22</a>]. Cephalosporins, including novel ones, appear to be proconvulsive, especially in patients with epilepsy [<a href="#CR22">22</a>]. Not only are resistant bacteria more difficult to control in case of infection, but surgical antibiotic prophylaxis has also become less effective, as evidenced for example by an increase in bacteremia after invasive urological procedures despite fluoroquinolone prophylaxis [<a href="#CR20">20</a>â€¢]. This is an important point to keep in mind for Emergency Department doctors when these patients present.</p> <p id="Par11">Other important mechanisms for development and spread of resistant bacteria have been recently emphasized. For example, many bacteria and fungi have the ability to form biofilms by both free living and pathogenic species, thereby limiting local antibiotic penetration [<a href="#CR5">5</a>]. Chronic infection in rhinosinusitis, purulent ulcers, and cystic fibrosis seem to be due to biofilms in large part [<a href="#CR2">2</a>â€¢]. As another example, <i>Pseudomonas aeruginosa</i> resistance to fluoroquinolones may be induced by diltiazem, a commonly used calcium channel blocker [<a href="#CR2">2</a>â€¢].</p> <p id="Par12">Even when an antibiotic is withdrawn, or its use restricted, it does not guarantee that a bacterium will become susceptible to it again. Multidrug-resistant traits do not affect Gonorrhea biological fitness, so it persists despite the lack of antibiotic exposure selection pressure [<a href="#CR23">23</a>].</p> <p id="Par13">Broad-spectrum antibiotic use puts patients at risk for developing <i>Clostridium difficile</i> colitis (CDI). A recent Cochrane review emphasized increased symptomatic cure with vancomycin when compared to metronidazole, fidaxomicin compared to vancomycin, and possibly teicoplanin compared to vancomycin [<a href="#CR24">24</a>] in CDI patients. Importantly, no recent studies looked at optimal treatment of severe <i>C. difficile</i> colitis [<a href="#CR24">24</a>].</p> </div> <div class="conclusion" title="sec"> <div class="title" tagx="title" title="title">
Conclusion</div> <p id="Par14">Even though many clinicians are alarmed at the slow and uneven pace of the new antibiotics development [<a href="#CR2">2</a>â€¢, <a href="#CR20">20</a>â€¢], a good many antimicrobial agents are now on the market (Table <a href="#Tab2">2</a>) as well as new anti-tuberculosis and antiviral medications (Table <a href="#Tab3">3</a>) since our last paper was published. Opening up new indications for old antibiotics becomes an increasingly important topic (Table <a href="#Tab4">4</a>) with a few stories of success over the yearsâ€"anti-community MRSA armamentarium includes doxycycline and trimethoprim-sulfamethoxazole, while the new research focuses on testing old antibiotics for <i>Neisseria gonorrhoeae</i> treatment and using anti-inflammatory properties of antibiotics in treatment of progressive degenerative neurological disorders. Several promising molecules are undergoing trials to establish their efficacy as therapeutic agents (Table <a href="#Tab5">5</a>). Unfortunately, if the history is any guide, only select few will become available for use for an Emergency Physician any time soon [<a href="#CR2">2</a>â€¢, <a href="#CR19">19</a>]. <div class="table-wrap_UNKNOWN" id="Tab2"><span class="label" tagx="label" title="label">Table 2</span> </div></p><p>Select new FDA-approved antibiotics on the market in the USA since year 2017 Google Scholar and Medscape Search [<a href="#CR25">25</a>â€"<a href="#CR27">27</a>]</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Drug class</th> <th>Names and notes</th> <th>Indications</th> <th>Select side effects</th> <th>Comments</th> </tr> </thead> <tbody> <tr> <td>Aminomethylcyclines</td> <td>Omadacycline</td> <td>Skin and soft tissue infections, pneumonia caused by Gram-positive pathogens including MRSA, <i>S. pneumonia</i> and VRE, some Gram negatives, Fragilis, Legionella, and Chlamydia</td> <td>Similar to newer tetracyclines such as doxycycline</td> <td>In trials for pneumonia treatment mortality rate was higher in omadacycline group</td> </tr> <tr> <td>Tetracyclines</td> <td>Sarecycline</td> <td>Approved for treatment of acne vulgaris.</td> <td>Similar to newer tetracyclines such as doxycycline</td> <td /> </tr> <tr> <td>Tetracyclines</td> <td>Eravacycline</td> <td>Complicated intraabdominal infections have broad-spectrum activity for treatment of Gram+ and Gramâˆ’ intraabdominal infections</td> <td>Infusion site reaction, tetracycline class adverse reactions</td> <td>Related to tigecycline. Not approved for urinary tract infections</td> </tr> <tr> <td>Aminoglycoside</td> <td>Plazomicin</td> <td>Complicated UTI and ventilator-associated pneumonia [<a href="#CR28">28</a>] caused by Gram-negative pathogens when no other treatment option exists</td> <td>Acute kidney injury, especially in patients with renal disease. Aminoglycoside class adverse reaction including at times irreversible ototoxicity, especially in patients with family history of hearing problems and neuromuscular blockade, especially in patients with preexisting neuromuscular disorders</td> <td /> </tr> <tr> <td>Nitroimidazole</td> <td>Pretomanid</td> <td>Limited patient populations with extensively drug resistant or non-responsive with multidrug-resistant <i>M. tuberculosis</i> infection only in combination with bedaquiline and linezolid</td> <td>Hepatotoxicity, myelosuppression, neurotoxicity, QT prolongation, lactic acidosis, multiple drug-drug interactions</td> <td /> </tr> <tr> <td>Fluoroquinolones</td> <td>Delafloxacin [<a href="#CR29">29</a>]</td> <td>Broad spectrum including MRSA, other Gram positives and Gram negatives for skin and soft tissue infections</td> <td>Carries the same black box warning as other fluoroquinolones, appears to have less QTc prolongation compared to other fluoroquinolones</td> <td /> </tr> <tr> <td>Rifamycins</td> <td>Rifamycin</td> <td>Travelerâ€™s diarrhea caused by noninvasive <i>E. coli</i> in adults</td> <td>Dyspepsia; generally low risk of side effects</td> <td>Not for patient with diarrhea associated with fever or bloody stools</td> </tr> <tr> <td>Nitroimidazole</td> <td>Secnidazole</td> <td>Treatment of bacterial vaginosis</td> <td>Candidal vulvovaginitis</td> <td>Single-dose treatment</td> </tr> <tr> <td>Carbapenem with Î² lactam inhibitor</td> <td>Meropenem/vaborbactam</td> <td>Complicated UTIs caused by Gram-negative organisms</td> <td>Risk of seizures with meropenem in patients with CNS disorders, reduced valproic acid serum concentration</td> <td /> </tr> <tr> <td>Cephalosporin</td> <td>Cefideracol [<a href="#CR30">30</a>]</td> <td>Complicated UTIs caused by MDR Gram negatives with no other option, has been used for treatment of ventilator-associated pneumonia [<a href="#CR28">28</a>]</td> <td /> <td>Increased mortality in critically ill patient with pneumonia or sepsis with carbapenem-resistant pathogens observed</td> </tr> <tr> <td>Pleuromutilin</td> <td>Lefamulin</td> <td>Community-acquired pneumonia, active against S. pneumonia, H. flu, Legionella, C. pneumonia, MSSA, mycoplasma</td> <td>Potential for QT prolongation, fetal toxicity, multiple drug-drug interactions</td> <td>Oral and injectable formulations are available</td> </tr> <tr> <td>Imipenem/cilastatin/relebactam</td> <td>Carbapenem/dehydropeptidase inhibitor/B-lactamase inhibitor</td> <td>Complicated UTIs and intraabdominal infection in patients where no alternative treatment is available</td> <td>Risk of seizures with carbapenem antibiotics in patients with CNS disorders may decrease valproic acid serum concentrations</td> <td /> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p><i>VRE</i> vancomycin-resistant enterococcus, <i>MDR</i> multidrug resistant, <i>MSSA</i> methicillin-sensitive <i>Staphylococcus aureus</i>, <i>MRSA</i> methicillin-resistant <i>Staphylococcus aureus</i></p> </div>  <div class="table-wrap_UNKNOWN" id="Tab3"><span class="label" tagx="label" title="label">Table 3</span> <p>Select new FDA-approved anti-tuberculosis drugs and antivirals on the market in the USA since year 2017</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Drug class</th> <th>Names and notes</th> <th>Indications</th> <th>Side effects</th> <th>Comments</th> </tr> </thead> <tbody> <tr> <td>Antiviral protein inhibitor</td> <td>Tecovirimat</td> <td>Small pox in adults and children</td> <td>Headache in healthy volunteers; hypoglycemia when combined with repaglinide</td> <td>Available through Strategic national Stockpile. Unknown efficacy in humans</td> </tr> <tr> <td>Endonuclease inhibitor</td> <td>Baloxavir marboxil</td> <td>Influenza up to 48Â h in duration in patients 12Â years of age or older</td> <td>No significant side effects described</td> <td>Single-dose completes the course of treatment, avoid co administration with antacids, laxatives, or oral supplements</td> </tr> <tr> <td>Non-nucleoside reverse transcriptase inhibitor</td> <td>Doravirine</td> <td>Combination therapy for HIV infection</td> <td>Uncommon; immune reconstitution inflammatory syndrome</td> <td>Do not co-administer strong cytochrome P450 enzyme inducers</td> </tr> <tr> <td>Monoclonal anti MDR HIV antibody</td> <td>Ibalizumab-uiyk</td> <td>MDR HIV infection</td> <td>Diarrhea, rash; immune reconstitution inflammatory syndrome</td> <td /> </tr> <tr> <td>Anti-hepatitis C combination drug</td> <td>Glecaprevir and pibrentasvir</td> <td>Hepatitis C infection</td> <td>Reactivation of hepatitis B that can result in fulminant hepatitis; worsening liver failure;</td> <td>Contraindicated in patients with severe liver impairment; avoid co-administering strong cytochrome P450 enzyme inducers</td> </tr> <tr> <td>Anti-hepatitis C combination drug</td> <td>Sofosbuvir/velpatasvir/voxilaprevir</td> <td>Hepatitis C infection</td> <td>Reactivation of hepatitis B that can result in fulminant hepatitis, case reports of severe bradycardia when amiodarone is co-administered; headache</td> <td>Not recommended in patients with moderate to severe hepatic impairment; do not co administer rifampin;</td> </tr> </tbody> </table> </div> <div class="table-wrap_UNKNOWN" id="Tab4"><span class="label" tagx="label" title="label">Table 4</span> <p>Select new indications for old antibiotics [<a href="#CR23">23</a>, <a href="#CR31">31</a>]</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Name</th> <th>Explored new indications</th> <th>Comments</th> </tr> </thead> <tbody> <tr> <td>Gentamicin, kanamycin</td> <td><i>N. gonorrhoeae</i> infections</td> <td /> </tr> <tr> <td>Ertapenem</td> <td><i>N. gonorrhoeae</i> infections</td> <td /> </tr> <tr> <td>Fosfomycin</td> <td><i>N. gonorrhoeae</i> infections</td> <td /> </tr> <tr> <td>Spectinomycin</td> <td><i>N. gonorrhoeae</i> infections</td> <td>First developed in 1960, abandoned after resistance emerged and new agents appeared, used again in some European countries, China, and South Korea [<a href="#CR23">23</a>]</td> </tr> <tr> <td>Ramoplanin</td> <td><i>Clostridium difficile</i></td> <td>Not absorbed from oral administration</td> </tr> <tr> <td>Minocycline</td> <td>MRSA</td> <td /> </tr> <tr> <td>Mecillinam [<a href="#CR32">32</a>]</td> <td>MDR Enterobacteriaceae</td> <td>Not available in the USA</td> </tr> <tr> <td>Tetracyclines, Î²-lactams, microcyclics</td> <td>Neuroprotection in Parkinsonâ€™s disease [<a href="#CR33">33</a>]</td> <td>Exploring anti-inflammatory properties</td> </tr> <tr> <td>Nebulized antibiotics formulations</td> <td>Amikacin, ciprofloxacin for ventilator-associated pneumonia [<a href="#CR28">28</a>]</td> <td>Currently only colistin, aztreonam, and tobramycin improved for use exclusively in patients with cystic fibrosis</td> </tr> </tbody> </table> </div> <div class="table-wrap_UNKNOWN" id="Tab5"><span class="label" tagx="label" title="label">Table 5</span> <p>Select novel antibiotics in development [<a href="#CR23">23</a>, <a href="#CR31">31</a>, <a href="#CR34">34</a>] Google Scholar search</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Drug class</th> <th>Names and notes</th> <th>Indications</th> <th>Comments</th> </tr> </thead> <tbody> <tr> <td>Defensins [<a href="#CR5">5</a>]</td> <td>Brilacidin</td> <td>Broad-spectrum antibacterial activity</td> <td /> </tr> <tr> <td>Medicinal leech and other animal venom as source for antimicrobial peptides [<a href="#CR35">35</a>, <a href="#CR36">36</a>]</td> <td>Several peptides are studied</td> <td /> <td>Interest based on ability of leech to store blood for a long time</td> </tr> <tr> <td>Extremophile bacteria as sources of antibiotics [<a href="#CR36">36</a>, <a href="#CR37">37</a>]</td> <td /> <td /> <td>Fusaricidin B isolated from hot springâ€"derived bacteria is assigned a new application for tuberculosis treatment</td> </tr> <tr> <td>Fluoroketolides</td> <td>Solithromycin [<a href="#CR23">23</a>]</td> <td>Activity against <i>N. gonorrhoeae</i>, <i>C. trachomatis</i>, <i>M. genitalium</i>, and Gram-positive respiratory pathogens</td> <td /> </tr> <tr> <td>Spiropyrimidinetrione topoisomerase II inhibitor</td> <td>Zoliflodacin</td> <td>Activity against XDR <i>N. gonorrhoeae</i> and C. trachomatis</td> <td /> </tr> <tr> <td>Triazaacenaphthylenes</td> <td>Gepotidacin</td> <td>Activity against MRSA, ESBL Enterobacteriaceae, and <i>N. gonorrhoeae</i></td> <td /> </tr> <tr> <td>Cephalosporin/vancomycin heterodimer</td> <td>Cefilavancin</td> <td>Gram-positive pathogens</td> <td /> </tr> <tr> <td>Ethambutol</td> <td>SQ 109</td> <td><i>M. tuberculosis</i></td> <td /> </tr> <tr> <td>Non-absorbable small molecule antibiotic</td> <td>Ridinilazole</td> <td><i>Clostridium difficile</i> all strains</td> <td>Granted fast track status by FDA</td> </tr> <tr> <td>Polymixins [<a href="#CR38">38</a>]</td> <td>NAB741, CB-182804</td> <td>Gram negatives</td> <td>Early stages</td> </tr> <tr> <td>Peptidomimetic</td> <td>Murepavadin [<a href="#CR28">28</a>, <a href="#CR39">39</a>]</td> <td><i>P. aeruginosa</i> infections</td> <td>Novel mechanism of action pseudomonas specific</td> </tr> <tr> <td>Carbapenems</td> <td>Tebipenem [<a href="#CR40">40</a>]</td> <td>Broad spectrum</td> <td>First carbapenem with oral formulation available</td> </tr> <tr> <td>Fluoroquinolones</td> <td>Nemonoxacin; zabofloxacin</td> <td>Broad spectrum with anti MRSA activity</td> <td>Approved and used in several countries</td> </tr> <tr> <td>Boronic acids</td> <td>RPX7009 [<a href="#CR41">41</a>]</td> <td /> <td>B-Lactamase inhibitors</td> </tr> </tbody> </table> </div> <p /> </div> </div> <div class="back" title="back"> <div class="fn-group" title="fn-group"> <div class="fn-type-" title=""> <p>This article is part of the Topical collection on <i>Infectious Disease</i></p> </div> <div class="fn-type-" title=""> <p><b>Publisherâ€™s Note</b></p> <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p> </div> </div> <div class="ack" title="ack"> <p>The authors wish to thank Dr. David Effron for reviewing their manuscript.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
Papers of particular interest, published recently, have been highlighted as: â€¢ Of importance â€¢â€¢ Of major importance</div> <li tag="ref"><a name="CR1" /><span class="label" tagx="label" title="label">1.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tacconelli</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carrara</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Savoldi</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</span><span class="source" tagx="source" title="source">Lancet Infect Dis</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">18</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">318</span><span class="lpage" tagx="lpage" title="lpage">327</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S1473-3099(17)30753-3">10.1016/S1473-3099(17)30753-3</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29276051">29276051</a></span></span></li> <li tag="ref"><a name="CR2" /><span class="label" tagx="label" title="label">2.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Frieri</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kumar</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boutin</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antibiotic resistance</span><span class="source" tagx="source" title="source">J Infect Public Health</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">10</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">369</span><span class="lpage" tagx="lpage" title="lpage">378</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jiph.2016.08.007">10.1016/j.jiph.2016.08.007</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27616769">27616769</a></span></span></li> <li tag="ref"><a name="CR3" /><span class="label" tagx="label" title="label">3.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazer-Amirshahi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pourmand</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">May</span><span class="given-names" tagx="given-names" title="given-names">L</span></span></span><span class="mixed-article-title" title="mixed-article-title">Newly approved antibiotics and antibiotics reserved for resistant infections: implications for emergency medicine</span><span class="source" tagx="source" title="source">Am J Emerg Med</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">35</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">154</span><span class="lpage" tagx="lpage" title="lpage">158</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ajem.2016.10.034">10.1016/j.ajem.2016.10.034</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28029487">28029487</a></span></span></li> <li tag="ref"><a name="CR4" /><span class="label" tagx="label" title="label">4.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hussain</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Galvin</span><span class="given-names" tagx="given-names" title="given-names">HD</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haw</span><span class="given-names" tagx="given-names" title="given-names">TY</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Drug resistance in influenza A virus: the epidemiology and management</span><span class="source" tagx="source" title="source">Infect Drug Resist</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">10</span><span class="fpage" tagx="fpage" title="fpage">121</span><span class="lpage" tagx="lpage" title="lpage">134</span><span class="pub-id"><a href="https://dx.doi.org/10.2147/IDR.S105473">10.2147/IDR.S105473</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28458567">28458567</a></span></span></li> <li tag="ref"><a name="CR5" /><span class="label" tagx="label" title="label">5.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Banin</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hughes</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kuipers</span><span class="given-names" tagx="given-names" title="given-names">OP</span></span></span><span class="mixed-article-title" title="mixed-article-title">Editorial: Bacterial pathogens, antibiotics and antibiotic resistance</span><span class="source" tagx="source" title="source">FEMS Microbiol Rev</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">41</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">450</span><span class="lpage" tagx="lpage" title="lpage">452</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/femsre/fux016">10.1093/femsre/fux016</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28486583">28486583</a></span></span></li> <li tag="ref"><a name="CR6" /><span class="label" tagx="label" title="label">6.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Burnham</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olsen</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kollef</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span></span><span class="mixed-article-title" title="mixed-article-title">Re-estimating annual deaths due to multidrug-resistant organism infections</span><span class="source" tagx="source" title="source">Infect Control Hosp Epidemiol</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">40</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">112</span><span class="lpage" tagx="lpage" title="lpage">113</span><span class="pub-id"><a href="https://dx.doi.org/10.1017/ice.2018.304">10.1017/ice.2018.304</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30463634">30463634</a></span></span></li> <li tag="ref"><a name="CR7" /><span class="label" tagx="label" title="label">7.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pourmand</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazer-Amirshahi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jasani</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Emerging trends in antibiotic resistance: implications for emergency medicine</span><span class="source" tagx="source" title="source">Am J Emerg Med</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">35</span><span class="issue" tagx="issue" title="issue">8</span><span class="fpage" tagx="fpage" title="fpage">1172</span><span class="lpage" tagx="lpage" title="lpage">1176</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ajem.2017.03.010">10.1016/j.ajem.2017.03.010</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28302376">28302376</a></span></span></li> <li tag="ref"><a name="CR8" /><span class="label" tagx="label" title="label">8.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shane</span><span class="given-names" tagx="given-names" title="given-names">AL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">SÃ¡nchez</span><span class="given-names" tagx="given-names" title="given-names">PJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stoll</span><span class="given-names" tagx="given-names" title="given-names">BJ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Neonatal sepsis</span><span class="source" tagx="source" title="source">Lancet</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">390</span><span class="issue" tagx="issue" title="issue">10104</span><span class="fpage" tagx="fpage" title="fpage">1770</span><span class="lpage" tagx="lpage" title="lpage">1780</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0140-6736(17)31002-4">10.1016/S0140-6736(17)31002-4</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28434651">28434651</a></span></span></li> <li tag="ref"><a name="CR9" /><span class="label" tagx="label" title="label">9.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Walker</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kenny</span><span class="given-names" tagx="given-names" title="given-names">CB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goel</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">Neonatal sepsis</span><span class="source" tagx="source" title="source">Paediatr Child Health</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">29</span><span class="issue" tagx="issue" title="issue">6</span><span class="fpage" tagx="fpage" title="fpage">263</span><span class="lpage" tagx="lpage" title="lpage">268</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.paed.2019.03.003">10.1016/j.paed.2019.03.003</a></span></span></li> <li tag="ref"><a name="CR10" /><span class="label" tagx="label" title="label">10.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koszalka</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tilmanis</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hurt</span><span class="given-names" tagx="given-names" title="given-names">AC</span></span></span><span class="mixed-article-title" title="mixed-article-title">Influenza antivirals currently in late-phase clinical trial</span><span class="source" tagx="source" title="source">Influenza Other Respir Viruses</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">11</span><span class="fpage" tagx="fpage" title="fpage">240</span><span class="lpage" tagx="lpage" title="lpage">246</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/irv.12446">10.1111/irv.12446</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28146320">28146320</a></span></span></li> <li tag="ref"><a name="CR11" /><span class="label" tagx="label" title="label">11.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ison</span><span class="given-names" tagx="given-names" title="given-names">MG</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antiviral treatments</span><span class="source" tagx="source" title="source">Clin Chest Med</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">38</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">139</span><span class="lpage" tagx="lpage" title="lpage">153</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ccm.2016.11.008">10.1016/j.ccm.2016.11.008</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28159156">28159156</a></span></span></li> <li tag="ref"><a name="CR12" /><span class="label" tagx="label" title="label">12.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Fangman Chen Hao Xu Jinli Liu etc Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and metaâ€�analysis J Oral Pathol Med 2017;46:561â€"568</span></li> <li tag="ref"><a name="CR13" /><span class="label" tagx="label" title="label">13.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Kristen M, Bullard-Feibelman, Jennifer Govero, ZheZhu etc The FDA-approved drug sofosbuvir inhibits Zika virus infection Antiviral Research Vol. 137. 2017;137:134â€"140</span></li> <li tag="ref"><a name="CR14" /><span class="label" tagx="label" title="label">14.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Benedict</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Richardson</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vallabhaneni</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks</span><span class="source" tagx="source" title="source">Lancet Infect Dis</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">17</span><span class="issue" tagx="issue" title="issue">12</span><span class="fpage" tagx="fpage" title="fpage">403</span><span class="lpage" tagx="lpage" title="lpage">411</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S1473-3099(17)30443-7">10.1016/S1473-3099(17)30443-7</a></span></span></li> <li tag="ref"><a name="CR15" /><span class="label" tagx="label" title="label">15.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Campoy</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Adrio</span><span class="given-names" tagx="given-names" title="given-names">JL</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antifungals</span><span class="source" tagx="source" title="source">Biochem Pharmacol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">133</span><span class="fpage" tagx="fpage" title="fpage">86</span><span class="lpage" tagx="lpage" title="lpage">96</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.bcp.2016.11.019">10.1016/j.bcp.2016.11.019</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27884742">27884742</a></span></span></li> <li tag="ref"><a name="CR16" /><span class="label" tagx="label" title="label">16.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Perlin</span><span class="given-names" tagx="given-names" title="given-names">DS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rautemaa-Richardson</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alastruey-Izquierdo</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">The global problem of antifungal resistance: prevalence, mechanisms, and management</span><span class="source" tagx="source" title="source">Lancet Infect Dis</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">17</span><span class="issue" tagx="issue" title="issue">12</span><span class="fpage" tagx="fpage" title="fpage">383</span><span class="lpage" tagx="lpage" title="lpage">392</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S1473-3099(17)30316-X">10.1016/S1473-3099(17)30316-X</a></span></span></li> <li tag="ref"><a name="CR17" /><span class="label" tagx="label" title="label">17.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kawasaki</span><span class="given-names" tagx="given-names" title="given-names">T</span></span></span><span class="mixed-article-title" title="mixed-article-title">Update on pediatric sepsis: a review</span><span class="source" tagx="source" title="source">J Intensive Care</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">5</span><span class="fpage" tagx="fpage" title="fpage">47</span><span class="pub-id"><a href="https://dx.doi.org/10.1186/s40560-017-0240-1">10.1186/s40560-017-0240-1</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28729906">28729906</a></span></span></li> <li tag="ref"><a name="CR18" /><span class="label" tagx="label" title="label">18.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gottlieb</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DeMott</span><span class="given-names" tagx="given-names" title="given-names">JM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hallock</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">Systemic antibiotics for the treatment of skin and soft tissue abscesses: a systematic review and meta-analysis</span><span class="source" tagx="source" title="source">Ann Emerg Med</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">73</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">8</span><span class="lpage" tagx="lpage" title="lpage">16</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.annemergmed.2018.02.011">10.1016/j.annemergmed.2018.02.011</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29530658">29530658</a></span></span></li> <li tag="ref"><a name="CR19" /><span class="label" tagx="label" title="label">19.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fernandes</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martens</span><span class="given-names" tagx="given-names" title="given-names">E</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antibiotics in late clinical development</span><span class="source" tagx="source" title="source">Biochem Pharmacol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">133</span><span class="fpage" tagx="fpage" title="fpage">152</span><span class="lpage" tagx="lpage" title="lpage">163</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.bcp.2016.09.025">10.1016/j.bcp.2016.09.025</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27687641">27687641</a></span></span></li> <li tag="ref"><a name="CR20" /><span class="label" tagx="label" title="label">20.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Friedman</span><span class="given-names" tagx="given-names" title="given-names">ND</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Temkin</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carmeli</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span></span><span class="mixed-article-title" title="mixed-article-title">The negative impact of antibiotic resistance</span><span class="source" tagx="source" title="source">Clin Microbiol Infect</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">22</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">416</span><span class="lpage" tagx="lpage" title="lpage">422</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.cmi.2015.12.002">10.1016/j.cmi.2015.12.002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26706614">26706614</a></span></span></li> <li tag="ref"><a name="CR21" /><span class="label" tagx="label" title="label">21.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dupont</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Prat</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sztrymf</span><span class="given-names" tagx="given-names" title="given-names">B</span></span></span><span class="mixed-article-title" title="mixed-article-title">Linezolid versus vancomycin in Methicillin Resistant <i>Staphylococcus aureus</i> nosocomial pneumonia in the elderly</span><span class="source" tagx="source" title="source">Am J Emerg Med</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">35</span><span class="issue" tagx="issue" title="issue">8</span><span class="fpage" tagx="fpage" title="fpage">1197</span><span class="lpage" tagx="lpage" title="lpage">1198</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ajem.2017.05.043">10.1016/j.ajem.2017.05.043</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28576638">28576638</a></span></span></li> <li tag="ref"><a name="CR22" /><span class="label" tagx="label" title="label">22.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Imani</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Buscher</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marriott</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Too much of a good thing: a retrospective study of Î²-lactam concentrationâ€"toxicity relationships</span><span class="source" tagx="source" title="source">J Antimicrob Chemother</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">72</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">2891</span><span class="lpage" tagx="lpage" title="lpage">2897</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/jac/dkx209">10.1093/jac/dkx209</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29091190">29091190</a></span></span></li> <li tag="ref"><a name="CR23" /><span class="label" tagx="label" title="label">23.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alirol</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wi</span><span class="given-names" tagx="given-names" title="given-names">TE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bala</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bazzo</span><span class="given-names" tagx="given-names" title="given-names">ML</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">X-S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Deal</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines</span><span class="source" tagx="source" title="source">PLoS Med</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">14</span><span class="issue" tagx="issue" title="issue">7</span><span class="fpage" tagx="fpage" title="fpage">e1002366</span><span class="pub-id"><a href="https://dx.doi.org/10.1371/journal.pmed.1002366">10.1371/journal.pmed.1002366</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28746372">28746372</a></span></span></li> <li tag="ref"><a name="CR24" /><span class="label" tagx="label" title="label">24.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for <i>Clostridium difficile</i>-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3).</span></li> <li tag="ref"><a name="CR25" /><span class="label" tagx="label" title="label">25.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Butler</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Blaskovich</span><span class="given-names" tagx="given-names" title="given-names">MAT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cooper</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antibiotics in the clinical pipeline at the end of 2015</span><span class="source" tagx="source" title="source">J Antibiot</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">70</span><span class="fpage" tagx="fpage" title="fpage">3</span><span class="lpage" tagx="lpage" title="lpage">24</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/ja.2016.72">10.1038/ja.2016.72</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27353164">27353164</a></span></span></li> <li tag="ref"><a name="CR26" /><span class="label" tagx="label" title="label">26.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abbas</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paul</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huttner</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">New and improved? a review of novel antibiotics for Gram-positive bacteria</span><span class="source" tagx="source" title="source">Clin Microbiol Infect</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">23</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">697</span><span class="lpage" tagx="lpage" title="lpage">703</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.cmi.2017.06.010">10.1016/j.cmi.2017.06.010</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28642145">28642145</a></span></span></li> <li tag="ref"><a name="CR27" /><span class="label" tagx="label" title="label">27.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">David</span><span class="given-names" tagx="given-names" title="given-names">MZ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dryden</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gottlieb</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Recently approved antibacterials for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and other Gram-positive pathogens: the shock of the new</span><span class="source" tagx="source" title="source">Int J Antimicrob Agents</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">50</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">303</span><span class="lpage" tagx="lpage" title="lpage">307</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ijantimicag.2017.05.006">10.1016/j.ijantimicag.2017.05.006</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28666751">28666751</a></span></span></li> <li tag="ref"><a name="CR28" /><span class="label" tagx="label" title="label">28.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bassetti</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vena</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Castaldo</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">New antibiotics for ventilator-associated pneumonia</span><span class="source" tagx="source" title="source">Curr Opin Infect Dis</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">31</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">177</span><span class="lpage" tagx="lpage" title="lpage">186</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/QCO.0000000000000438">10.1097/QCO.0000000000000438</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29337703">29337703</a></span></span></li> <li tag="ref"><a name="CR29" /><span class="label" tagx="label" title="label">29.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ocheretyaner</span><span class="given-names" tagx="given-names" title="given-names">ER</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and <i>Pseudomonas aeruginosa</i></span><span class="source" tagx="source" title="source">Expert Rev Anti-Infect Ther</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">16</span><span class="issue" tagx="issue" title="issue">7</span><span class="fpage" tagx="fpage" title="fpage">523</span><span class="lpage" tagx="lpage" title="lpage">530</span><span class="pub-id"><a href="https://dx.doi.org/10.1080/14787210.2018.1489721">10.1080/14787210.2018.1489721</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29911455">29911455</a></span></span></li> <li tag="ref"><a name="CR30" /><span class="label" tagx="label" title="label">30.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Choi</span><span class="given-names" tagx="given-names" title="given-names">JJ</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cefiderocol: a novel siderophore cephalosporin</span><span class="source" tagx="source" title="source">Expert Opin Investig Drugs</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">27</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">193</span><span class="lpage" tagx="lpage" title="lpage">197</span><span class="pub-id"><a href="https://dx.doi.org/10.1080/13543784.2018.1426745">10.1080/13543784.2018.1426745</a></span></span></li> <li tag="ref"><a name="CR31" /><span class="label" tagx="label" title="label">31.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BassÃ¨res</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Endres</span><span class="given-names" tagx="given-names" title="given-names">BT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dotson</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel antibiotics in development to treat <i>Clostridium difficile</i> infection</span><span class="source" tagx="source" title="source">Curr Opin Gastroenterol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">33</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">7</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/MOG.0000000000000332">10.1097/MOG.0000000000000332</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28134686">28134686</a></span></span></li> <li tag="ref"><a name="CR32" /><span class="label" tagx="label" title="label">32.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zayyad</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eliakim-Raz</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leibovici</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paul</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">Revival of old antibiotics: needs, the state of evidence and expectations</span><span class="source" tagx="source" title="source">Int J Antimicrob Agents</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">49</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">536</span><span class="lpage" tagx="lpage" title="lpage">541</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ijantimicag.2016.11.021">10.1016/j.ijantimicag.2016.11.021</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28162982">28162982</a></span></span></li> <li tag="ref"><a name="CR33" /><span class="label" tagx="label" title="label">33.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reglodi</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Renaud</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tamas</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">Novel tactics for neuroprotection in Parkinson's disease: role of antibiotics, polyphenols and neuropeptides</span><span class="source" tagx="source" title="source">Prog Neurobiol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">155</span><span class="fpage" tagx="fpage" title="fpage">120</span><span class="lpage" tagx="lpage" title="lpage">148</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.pneurobio.2015.10.004">10.1016/j.pneurobio.2015.10.004</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26542398">26542398</a></span></span></li> <li tag="ref"><a name="CR34" /><span class="label" tagx="label" title="label">34.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mishra</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reiling</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zarena</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Host defense antimicrobial peptides as antibiotics: design and application strategies</span><span class="source" tagx="source" title="source">Curr Opin Chem Biol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">38</span><span class="fpage" tagx="fpage" title="fpage">87</span><span class="lpage" tagx="lpage" title="lpage">96</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.cbpa.2017.03.014">10.1016/j.cbpa.2017.03.014</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28399505">28399505</a></span></span></li> <li tag="ref"><a name="CR35" /><span class="label" tagx="label" title="label">35.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Grafskaia</span><span class="given-names" tagx="given-names" title="given-names">EN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nadezhdin</span><span class="given-names" tagx="given-names" title="given-names">KD</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Talyzina</span><span class="given-names" tagx="given-names" title="given-names">IA</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Medicinal leech antimicrobial peptides lacking toxicity represent a promising alternative strategy to combat antibiotic-resistant pathogens</span><span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">180</span><span class="fpage" tagx="fpage" title="fpage">143</span><span class="lpage" tagx="lpage" title="lpage">153</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ejmech.2019.06.080">10.1016/j.ejmech.2019.06.080</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31302447">31302447</a></span></span></li> <li tag="ref"><a name="CR36" /><span class="label" tagx="label" title="label">36.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Demain</span><span class="given-names" tagx="given-names" title="given-names">AL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GÃ³mez-Ortiz</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ruiz-VillafÃ¡n</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Recent findings of molecules with anti-infective activity: screening of non-conventional sources</span><span class="source" tagx="source" title="source">Curr Opin Pharmacol</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">48</span><span class="fpage" tagx="fpage" title="fpage">40</span><span class="lpage" tagx="lpage" title="lpage">47</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.coph.2019.04.003">10.1016/j.coph.2019.04.003</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31078095">31078095</a></span></span></li> <li tag="ref"><a name="CR37" /><span class="label" tagx="label" title="label">37.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahajan</span><span class="given-names" tagx="given-names" title="given-names">GB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Balachandran</span><span class="given-names" tagx="given-names" title="given-names">L</span></span></span><span class="mixed-article-title" title="mixed-article-title">Sources of antibiotics: hot springs</span><span class="source" tagx="source" title="source">Biochem Pharmacol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">134</span><span class="fpage" tagx="fpage" title="fpage">35</span><span class="lpage" tagx="lpage" title="lpage">41</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.bcp.2016.11.021">10.1016/j.bcp.2016.11.021</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27890726">27890726</a></span></span></li> <li tag="ref"><a name="CR38" /><span class="label" tagx="label" title="label">38.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brown</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dawson</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections</span><span class="source" tagx="source" title="source">J Antibiot</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">70</span><span class="fpage" tagx="fpage" title="fpage">386</span><span class="lpage" tagx="lpage" title="lpage">394</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/ja.2016.146">10.1038/ja.2016.146</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28074057">28074057</a></span></span></li> <li tag="ref"><a name="CR39" /><span class="label" tagx="label" title="label">39.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martin-Loeches</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dale</span><span class="given-names" tagx="given-names" title="given-names">GE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Torres</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">Murepavadin: a new antibiotic class in the pipeline</span><span class="source" tagx="source" title="source">Expert Rev Anti-Infect Ther</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">16</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">259</span><span class="lpage" tagx="lpage" title="lpage">268</span><span class="pub-id"><a href="https://dx.doi.org/10.1080/14787210.2018.1441024">10.1080/14787210.2018.1441024</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29451043">29451043</a></span></span></li> <li tag="ref"><a name="CR40" /><span class="label" tagx="label" title="label">40.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jain</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Utley</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parr</span><span class="given-names" tagx="given-names" title="given-names">TR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zabawa</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pucci</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tebipenem, the first oral carbapenem antibiotic</span><span class="source" tagx="source" title="source">Expert Rev Anti-Infect Ther</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">16</span><span class="issue" tagx="issue" title="issue">7</span><span class="fpage" tagx="fpage" title="fpage">513</span><span class="lpage" tagx="lpage" title="lpage">522</span><span class="pub-id"><a href="https://dx.doi.org/10.1080/14787210.2018.1496821">10.1080/14787210.2018.1496821</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30014729">30014729</a></span></span></li> <li tag="ref"><a name="CR41" /><span class="label" tagx="label" title="label">41.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GonzÃ¡lez-Bello</span><span class="given-names" tagx="given-names" title="given-names">C</span></span></span><span class="mixed-article-title" title="mixed-article-title">Recently developed synthetic compounds with anti-infective activity</span><span class="source" tagx="source" title="source">Curr Opin Pharmacol</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">48</span><span class="fpage" tagx="fpage" title="fpage">17</span><span class="lpage" tagx="lpage" title="lpage">23</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.coph.2019.03.004">10.1016/j.coph.2019.03.004</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31005786">31005786</a></span></span></li> </ul> </div> </ul> </div> </div>  </body></html>